Volume 101, Pages 1-8 (November 2016)

Slides:

Advertisements

Similar presentations

CT screening for lung cancer: Is the evidence strong enough? J.K. Field, A. Devaraj, S.W. Duffy, D.R. Baldwin Lung Cancer Volume 91, Pages (January.

Advertisements

Multiplex Ultrasensitive Genotyping of Patients with Non-Small Cell Lung Cancer for Epidermal Growth Factor Receptor (EGFR) Mutations by Means of Picodroplet.

A long-term survivor of non-small-cell lung cancer harboring concomitant EGFR mutation and ALK translocation Fumio Imamura, Takako Inoue, Madoka Kimura,

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Assessment of chemotherapy strategy using bevacizumab for non-squamous non-small cell lung cancer in a real-world setting: A multi-institutional observational.

Meta-analysis study of lymph node staging by 18 F-FDG PET/CT scan in non-small cell lung cancer: Comparison of TB and non-TB endemic regions Chih-Ying.

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Volume 79, Issue 1, Pages (January 2013)

Fig. 2. High-resolution melting curves for exon 21 of the EGFR gene

Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non- small-cell lung cancer (NSCLC) patients with good performance status.

Assessment of chemotherapy strategy using bevacizumab for non-squamous non-small cell lung cancer in a real-world setting: A multi-institutional observational.

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma Kazuya Takamochi, MD, Shiaki Oh, MD,

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Treatment decisions in metastatic colorectal cancer – Beyond first and second line combination therapies A. Vogel, R.D. Hofheinz, S. Kubicka, D. Arnold

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Crizotinib administered via nasogastric and percutaneous endoscopic gastrostomy tubes for the successful treatment of ALK-rearranged lung cancer in a.

New Patient Journeys in Non-small cell lung cancer

Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib Gouji Toyokawa, MD, PhD, Fumihiko Hirai, MD, PhD, Eiko.

Endobronchial Ultrasonography for Positron Emission Tomography and Computed Tomography–Negative Lymph Node Staging in Non-Small Cell Lung Cancer Masato.

Transbronchial Biopsy Needle Rinse Solution Used for Comprehensive Biomarker Testing in Patients with Lung Cancer Yuichi Sakairi, MD, PhD, Kenichi Sato,

Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review Swati Kulkarni, MD, Emily T. Vella,

Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) were constructed based on.

Uterine metastasis of lung adenocarcinoma revealed by the same epidermal growth factor receptor mutation in both lung and endometrial biopsies Noriko.

Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non– small-cell Lung Cancer Exhibiting Resistance to Ceritinib Gouji Toyokawa,

Phase I Clinical Study of the Angiogenesis Inhibitor TSU-68 Combined with Carboplatin and Paclitaxel in Chemotherapy-Naive Patients with Advanced Non-small.

A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer Katsuyuki Kiura,

Squamous-cell transformation in a patient with lung adenocarcinoma receiving erlotinib: Co-occurrence with T790M mutation Diogo D.G. Bugano, Neda Kalhor,

A Prospective Study of Surgical Procedures for Patients With Oligometastatic Non-Small Cell Lung Cancer Chiaki Endo, MD, PhD, Tohru Hasumi, MD, PhD,

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer Hiroyasu Kaneda, MD, PhD, Isamu.

Meghan Campo, MD, David Gerber, MD, Justin F. Gainor, MD, Rebecca S

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung.

Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non– Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI Akito Hata,

Small Cell Transformation and T790M Mutation as Coresistance Mechanisms for First- line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor.

Characterizing the Killer Colorectal Carcinomas

All for One: Multidisciplinary Management in EGFR-Mutated NSCLC

Photodynamic Therapy for Early Stage Central Type of Lung Cancer

Detection rate for EGFR mutations in cfDNA.

Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status Jean-Yves Douillard,

Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell–Free DNA from Patients with Advanced Non–Small Cell.

Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma Tzu-Hsiu Tsai,

Elliot Wakeam, MD, MPH, James P. Byrne, MD, Gail E

Clinical courses of patients.

Histology and Smoking Status Predict Survival of Patients with Advanced Non–Small- Cell Lung Cancer: Results of West Japan Oncology Group (WJOG) Study.

Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.

Jessica J. Lin, MD, Stephanie Cardarella, MD, Christine A

Do Complex Mutations of the Epidermal Growth Factor Receptor Gene Reflect Intratumoral Heterogeneity? Akito Hata, MD, Shiro Fujita, MD, PhD, Reiko Kaji,

Somatic Mutations of the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitor Response to TKIs in Non-small Cell Lung.

Erratum Journal of Thoracic Oncology

Phase I and Pharmacokinetic Study of Combination Chemotherapy Using Irinotecan and Paclitaxel in Patients with Lung Cancer Gyo Asai, MD, PhD, Nobuyuki.

EGFR Mutations Detected in Plasma Are Associated with Patient Outcomes in Erlotinib Plus Docetaxel-Treated Non-small Cell Lung Cancer Philip C. Mack,

Resisting Targeted Therapy: Fifty Ways to Leave Your EGFR

Ligands of Epidermal Growth Factor Receptor and the Insulin-Like Growth Factor Family as Serum Biomarkers for Response to Epidermal Growth Factor Receptor.

Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

XL647—A Multitargeted Tyrosine Kinase Inhibitor: Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding.

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas

The Feasibility of Median Sternotomy With or Without Thoracotomy for Locally Advanced Non-Small Cell Lung Cancer Treated With Induction Chemoradiotherapy

Monotherapy Administration of Sorafenib in Patients With Non–Small Cell Lung Cancer (MISSION) Trial Luis Paz-Ares, MD, Vera Hirsh, MD, Li Zhang, MD,

PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients Hideki Endoh, MD, PhD,

Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor–Resistant Non–Small Cell Lung Cancer Hiroaki Ogata,

A Phase II Trial of Erlotinib Monotherapy in Pretreated Patients with Advanced Non- small Cell Lung Cancer Who Do Not Possess Active EGFR Mutations: Okayama.

Christina S. Baik, MD, MPH, Marc C. Chamberlain, MD, Laura Q. Chow, MD

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Volume 163, Issue 4, (November 2015)

Good Response to Gefitinib in Lung Adenocarcinoma Harboring Coexisting EML4-ALK Fusion Gene and EGFR Mutation Yao-Wen Kuo, MD, Shang-Gin Wu, MD, Chao-Chi.

Phase II Trial of Amrubicin for Second-Line Treatment of Advanced Non-small Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial.

Patterns of clinical relapse and algorithm for the therapeutic strategy when AR to EGFR TKI occurs in patients with EGFR-mutant NSCLC. *After discussion.

Presentation transcript:

Volume 101, Pages 1-8 (November 2016) Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study Kaname Nosaki, Miyako Satouchi, Takayasu Kurata, Tatsuya Yoshida, Isamu Okamoto, Nobuyuki Katakami, Fumio Imamura, Kaoru Tanaka, Yuki Yamane, Nobuyuki Yamamoto, Terufumi Kato, Katsuyuki Kiura, Hideo Saka, Hiroshige Yoshioka, Kana Watanabe, Keiko Mizuno, Takashi Seto Lung Cancer Volume 101, Pages 1-8 (November 2016) DOI: 10.1016/j.lungcan.2016.07.007 Copyright © 2016 AstraZeneca K.K. Terms and Conditions

Fig. 1 Patient flow diagram. Lung Cancer 2016 101, 1-8DOI: (10.1016/j.lungcan.2016.07.007) Copyright © 2016 AstraZeneca K.K. Terms and Conditions

Fig. 2 Comparison between the initial biopsy and re-biopsy. a and b: Sampling site (n=395). Metastasis (n = 36 in Fig. 2a, n = 121 in Fig. 2b) includes distant metastasis, lung metastasis, and distant lymph node metastasis. c and d: Sampling site from metastasis. Abbreviation: pts, patients Lung Cancer 2016 101, 1-8DOI: (10.1016/j.lungcan.2016.07.007) Copyright © 2016 AstraZeneca K.K. Terms and Conditions

Fig. 3 Results of the EGFR mutation assay after re-biopsy. The number of patients with re-biopsy success was 314. EGFR mutation assay was conducted in 296 patients. The reasons not conducting EGFR mutation assay were other target mutation assays such as PD-L1 assay in 2 patients, PIK3CA assay in one patient, EML4-ALK assay was in 2 patients, transformation to small cell lung cancer in 12 patients. For the remaining 4 patients, the reason was unknown. Abbreviation: EGFR, epidermal growth factor receptor; pts, patients Lung Cancer 2016 101, 1-8DOI: (10.1016/j.lungcan.2016.07.007) Copyright © 2016 AstraZeneca K.K. Terms and Conditions

Fig. 4 Development of T790M mutation stratified by type of initial EGFR mutation and EGFR-TKI treatment. p=0.05 (Fisher’s exact test) for Del19 mutation vs L858R mutation. Abbreviation: EGFR, epidermal growth factor receptor Lung Cancer 2016 101, 1-8DOI: (10.1016/j.lungcan.2016.07.007) Copyright © 2016 AstraZeneca K.K. Terms and Conditions